As of December 2012, CIC has conducted 319 clinical trials, surpassing the target of 300 trials for 2012. Currently, CIC has contributed approximately 40% of the data and is expected to reach 70% of the target by year 2020.
Clinical trials are one of the Entry Points Project (EPP) under the 12 National Key Economic Areas (NKEAs) introduced by the government through the Economic Transformation Programme (ETP) to elevate the country to a developed nation by 2020. Clinical trials are under EPP 2: Creating Supportive Eco-system to Grow Clinical Research.
At the international level, CIC has won several prestigious awards including the recent award in Asian Manufacturing Awards 2013 for the category of Best Pharma Clinical Trials Service Provider. The winners of six main categories for this awards were determined by an independent jugding panel comprising 22 experts and practitioners, who examined 136 nominations received from 97 companies.
